Results 211 to 220 of about 467,873 (247)
Some of the next articles are maybe not open access.
JAMA: The Journal of the American Medical Association, 1989
The issue of what drug effects to measure, surrogate end points, has been emphasized by two recent clinical trials. Several recent studies have given us new information about why different people react so differently to the same dose of the same medicine.
openaire +5 more sources
The issue of what drug effects to measure, surrogate end points, has been emphasized by two recent clinical trials. Several recent studies have given us new information about why different people react so differently to the same dose of the same medicine.
openaire +5 more sources
Clinical pharmacology of progestins
Minerva Obstetrics and Gynecology, 2022In this paper, we report general pharmacological profile and major biological activities of natural progesterone (P) and progestins. The aim of this article consists of synthesizing the principal aspects of pharmacology and metabolism of P and progestins related to the clinical consequences of their use.We review scientific literature on the topic ...
Capozzi, Anna +2 more
openaire +3 more sources
Clinical pharmacology and malaria
Annals of Tropical Medicine And Parasitology, 1997The role of clinical pharmacology in improving the prevention and treatment of malaria is reviewed. A series of general and specific issues is discussed, concentrating on risk-benefit and cost-effectiveness. The techniques of clinical pharmacokinetics play an important role in the optimal use of drugs and this is illustrated by studies on quinine and ...
A M, Breckenridge, P A, Winstanley
openaire +2 more sources
The clinical pharmacology of eplerenone
Expert Opinion on Drug Metabolism & Toxicology, 2009Eplerenone is an aldosterone receptor antagonist indicated for the treatment of hypertension and congestive heart failure. Eplerenone contains an epoxy group, which offers greater mineralocorticoid receptor specificity. It is an effective antihypertensive that has been shown to reduce morbidity and mortality in individuals with left ventricular ...
James A, Muldowney +2 more
openaire +2 more sources
Pharmacology and Clinical Pharmacology of Vigabatrin
Journal of Child Neurology, 1991Vigabatrin is an enzyme-activated, irreversible inhibitor of γ-aminobutyric acid (GABA) aminotransferase, which causes a marked increase in cerebral GABA concentration and a resulting anticonvulsant action. Recovery from its effects requires the synthesis of new enzyme, and this may take several days following a single dose.
openaire +2 more sources
Clinical pharmacology in Australia
Clinical Pharmacology & Therapeutics, 1974In Australia, clinical pharmacology is a small but developing discipline useful for the generation of data concerning the efficacy and safety of new therapeutic substances. While most clinical pharmacology is carried on as an adiunct to the interests of a specialist in some branch of internal medicine, there are now, in Australia, four units titled ...
openaire +4 more sources
CLINICAL PHARMACOLOGY OF BENZODIAZEPINES
Annual Review of Medicine, 1987The benzodiazepines are the most widely used anxiolytic drugs. Their pharmacokinetic properties differ widely. Side effects are usually mild but dependence can supervene after long-term administration, even if normal therapeutic doses are not exceeded. Careful monitoring of use is essential.
openaire +2 more sources
To design therapeutic trials and select the most appropriate substance and dose for an indication, a detailed understanding of clinical pharmacology is crucial. In recent years, several studies have explored the human pharmacology of different psychedelics and 3,4-methylendioxymethylamphetamin (MDMA).
Severin B, Vogt, Matthias E, Liechti
openaire +2 more sources
Severin B, Vogt, Matthias E, Liechti
openaire +2 more sources
Clinical pharmacology of glipizide
The American Journal of Medicine, 1983The clinical pharmacology of glipizide and other sulfonylureas is briefly reviewed. Reevaluation of the University Group Diabetes Program data suggests that sulfonylureas do not increase cardiovascular mortality. Instead, a long-term study of subjects with impaired glucose tolerance indicates that sulfonylureas reduce the frequency of cardiovascular ...
A, Melander, E, Wåhlin-Boll
openaire +2 more sources
Pharmacology and clinical pharmacology of organic nitrates
European Journal of Clinical Pharmacology, 1990Current concepts and future aspects of pharmacological interventions in the treatment of coronary heart disease have been compiled. Especially new insights in the pathophysiology of coronary heart disease e.g. the dynamic pathology of coronary atherosclerosis, possible role of endothelin in vasospasm, as well as new pharmacodynamic and pharmacokinetic ...
openaire +2 more sources